Building not operational until 2019, says CEO
US insurers are covering the treatment, despite high price.
More patient involvement means all can benefit from their knowledge, as they are experts in their own health experience.
Can breath be the basis for the ultimate cancer screening tool?
The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.
02/11/2016November 1, 2016
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.